Table of Contents
Analgesics in Israel
Euromonitor International
May 2009
List of
Contents and Tables
Executive Summary
2008 Continues Positive Growth
Rates Similar To the Review Period
Demand for More Specific Treatments
Leads To New Innovations and Launches
Private Label Benefits From Unique
Market Structure
Gsl Revolution Did Not Bring Expected Results
Economic Slowdown Aside, Some Sectors Are Expected To See Strong Growth
Key Trends and Developments
Unusual Market Structure With OTC Drugs
Falling in the "health Basket"
Increased Private Label Activity
Specific Drugs Answer Consumer Demand for Specification
Gsl Revolution
Failed To Impact the Retail Market As Expected
Economic Slowdown Is
Expected Only in 2009
Market Indicators
Table 1 Consumer Expenditure
on Health Goods and Medical Services 2003-2008
Table 2 Life Expectancy at
Birth 2003-2008
Market Data
Table 3 Sales of OTC Healthcare by Sector:
Value 2003-2008
Table 4 Sales of OTC Healthcare by Sector: % Value Growth
2003-2008
Table 5 OTC Healthcare Company Shares by Value 2004-2008
Table 6 OTC Healthcare Brand Shares by Value 2005-2008
Table 7 Penetration
of Private Label by Sector 2003-2008
Table 8 Sales of OTC Healthcare by
Distribution Format: % Analysis 2003-2008
Table 9 Sales of OTC Healthcare
by Sector and Distribution Format: % Analysis 2008
Table 10 Forecast Sales
of OTC Healthcare by Sector: Value 2008-2013
Table 11 Forecast Sales of
OTC Healthcare by Sector: % Value Growth 2008-2013
Appendix
OTC
Registration and Classification
Vitamins and Dietary Supplements
Registration and Classification
Self-medication and Preventive
Medicine
Generics
Switches
Summary 1 OTC Healthcare Switches
2005-2007
Definitions
Summary 2 Research Sources
Dexxon Ltd
Strategic Direction
Key Facts
Summary 3 Dexxon Ltd: Key Facts
Summary 4 Dexxon Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 5 Dexxon Ltd: Competitive
Position 2008
New-pharm Drugstores Ltd
Strategic Direction
Key
Facts
Summary 6 New-Pharm Drugstores Ltd: Key Facts
Summary 7
New-Pharm Drugstores Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Rekah Pharmaceutical Products
Ltd
Strategic Direction
Key Facts
Summary 8 Rekah Pharmaceutical
Products Ltd: Key Facts
Summary 9 Rekah Pharmaceutical Products Ltd:
Operational Indicators
Company Background
Production
Competitive
Positioning
Summary 10 Rekah Pharmaceutical Products Ltd: Competitive
Position 2008
Super-pharm (israel) Ltd
Strategic Direction
Key
Facts
Summary 11 Super Pharm Israel Ltd: Key Facts
Summary 12 Super
Pharm Israel Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Teva Pharmaceutical Industries
Ltd
Strategic Direction
Key Facts
Summary 13 Teva Pharmaceutical
Industries Ltd: Key Facts
Summary 14 Teva Pharmaceutical Industries Ltd:
Operational Indicators
Company Background
Production
Competitive
Positioning
Summary 15 Teva Pharmaceutical Industries Ltd: Competitive
Position 2008
Trima Israel Pharmaceutical Products Maabarot Ltd
Strategic Direction
Key Facts
Summary 16 Trima Israel Pharmaceutical
Products Maabarot Ltd: Key Facts
Summary 17 Trima Israel Pharmaceutical
Products Maabarot Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 18 Trima Israel
Pharmaceutical Products Maabarot Ltd Competitive Position 2008
Headlines
Trends
Switches
Competitive Landscape
Prospects
Sector Data
Table 12 Sales of Analgesics by Subsector: Value 2003-2008
Table 13 Sales of Analgesics by Subsector: % Value Growth 2003-2008
Table
14 Herbal vs Standard Topical Analgesics 2003-2008
Table 15 Topical
Analgesics by Format: % Value Breakdown 2004-2008
Table 16 Analgesics
Company Shares by Value 2004-2008
Table 17 Analgesics Brand Shares by
Value 2005-2008
Table 18 Forecast Sales of Analgesics by Subsector: Value
2008-2013
Table 19 Forecast Sales of Analgesics by Subsector: % Value
Growth 2008-2013
| 
View Cart
